Harvard University Stock Portfolio: Top 5 Picks

4. AbCellera Biologics Inc. (NASDAQ:ABCL)

Harvard Management Company’s Stake Value: $43,719,000

Number of Hedge Fund Holders: 17

AbCellera Biologics Inc. (NASDAQ:ABCL) is headquartered in Vancouver, Canada, and the company operates an AI-powered antibody discovery platform. Harvard University stock portfolio features 4.10 million shares of AbCellera Biologics Inc. (NASDAQ:ABCL) as of Q2 2022, worth $43.7 million and representing 5.06% of the total holdings. The stock has been part of the Harvard portfolio since Q4 2020. 

On August 10, Credit Suisse analyst Tiago Fauth maintained an Outperform rating on AbCellera Biologics Inc. (NASDAQ:ABCL) but lowered the price target on the shares to $34 from $40 following the Q2 results. The analyst observed that the company added six programs under contract and initiated discovery on four additional programs, bringing the cumulative program stats to 88. This represents a robust 47% year-over-year growth. However, there is some quarter-over-quarter variability across these metrics, the analyst added. 

According to Insider Monkey’s data, 17 hedge funds were bullish on AbCellera Biologics Inc. (NASDAQ:ABCL) at the end of June 2022, with combined stakes worth $320.5 million. Julian Baker and Felix Baker’s Baker Bros. Advisors is the largest stakeholder of the company, with 10.45 million shares valued at $111.3 million. 

Follow Abcellera Biologics Inc. (NASDAQ:ABCL)